AutologousMolecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Under a Creative Commons license
open archive
Key Words
Mantle cell lymphoma
Autologous stem cell transplantation
Minimal residual disease
Preemptive rituximab
Cited by (0)
Financial disclosure: See Acknowledgments on page 434.
© 2017 American Society for Blood and Marrow Transplantation.